Increased plasma adiponectin in losartan-treated type 1 diabetic patients. a mediator of improved insulin sensitivity?
Nielsen
S
S
Medical Departments of Endocrinology & Diabetes, Aarhus University Hospitals, Denmark. Nielsen.Soren@dadlnet.dk
Lihn
A S
AS
ØStergaard
T
T
Mogensen
C E
CE
Schmitz
O
O
D052242:Adiponectin; D000328:Adult; D057911:Angiotensin Receptor Antagonists; D001786:Blood Glucose / Q000378:metabolism; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D004311:Double-Blind Method; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood; D007328:Insulin / Q000494:pharmacology; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D009994:Osmolar Concentration; D010084:Oxidation-Reduction / Q000187:drug effects; D011506:Proteins / Q000378:metabolism*
D052242:Adiponectin; D057911:Angiotensin Receptor Antagonists; D001786:Blood Glucose; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; D019808:Losartan